The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
- Conditions
- Rectal Cancer Stage III
- Interventions
- Diagnostic Test: serum adipokines
- Registration Number
- NCT04598984
- Lead Sponsor
- Istanbul Training and Research Hospital
- Brief Summary
It has been shown that adipokines (resistin, leptin, adiponectin) secreted from adipose tissue and proinflammatory cytokines such as IL-6, TNF-a are associated with the risk of developing colorectal cancer. However, the role of these factors in predicting clinical response to neoadjuvant therapy in rectal cancers is unknown. In this study, the role of serum adipokine levels before neoadjuvant therapy in predicting clinical response in patients with rectal cancer is investigated. For this purpose, blood will be drawn from patients with rectal cancer who will receive neoadjuvant therapy, serum adipokines will be studied and clinical response to neoadjuvant therapy will be compared.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
- All patients with locally advanced rectal cancer
- below 18 years old
- patients who did not received neoadjuvant therapyAll
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description High levels of serum adipokines serum adipokines - Low levels of serum adipokines serum adipokines -
- Primary Outcome Measures
Name Time Method The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients with Rectal Cancer 1 year The Adiponectin, Adipsin, Leptin, Resistin levels will be measured with flow cytometric analysis.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Istanbul Training and Research Hospital
🇹🇷Istanbul, Turkey